Effective alternates to trimethoprim-sulfamethoxazole as antimicrobial prophylaxis in stem cell recipients: Are there any?

Pediatric Transplantation

Volumn 12, Issue 8, 2008, Pages 823-826

  Ramesh, Mayur ^a   Chandrasekar, Pranatharthi H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; FOLINIC ACID; PENTAMIDINE; PYRIMETHAMINE; SULFADIAZINE; SULFADOXINE;

AGRANULOCYTOSIS; ANAPHYLAXIS; APLASTIC ANEMIA; BLOOD TOXICITY; BRONCHOSPASM; COUGHING; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; ENCEPHALITIS; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; MENINGITIS; METHEMOGLOBINEMIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PNEUMOCYSTIS; PNEUMOCYSTOSIS; RASH; STEM CELL TRANSPLANTATION; TOXOPLASMA; TOXOPLASMOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTI-INFECTIVE AGENTS; DRUG DESIGN; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELLS; HUMANS; ORGAN TRANSPLANTATION; PNEUMONIA, PNEUMOCYSTIS; STEM CELL TRANSPLANTATION; TOXOPLASMOSIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 54849431805     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00987.x     Document Type: Editorial

References (38)

1. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten years' experience. Rev Infect Dis 1982 : 4 : 1119 1132.
2. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. Arch Intern Med 1995 : 155 : 1125 1127.
3. Martino R, Maertens J, Bretagne S, et al. Toxoplasmosis after hematopoietic stem cell transplantation. Clin Infect Dis 2000 : 31 : 1188 1195.
4. Martino R, Bretagne S, Rovira M, et al. Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for blood and marrow transplantation. Bone Marrow Transplant 2000 : 25 : 1111 1114.
5. Mele A, Paterson PJ, Prentice HG, Leoni P, Kibbler CC. Toxoplasmosis in bone marrow transplantation: A report of two cases and systematic review of the literature. Bone Marrow Transplant 2002 : 29 : 691 698.
6. Martino R. Toxoplasmosis after hematopoietic stem cell transplantation. In : Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections. Philadelphia : Lippincott Williams & Wilkins, 2003 : pp. 535 540.
7. Dykewicz CA, Centers for Disease control and Prevention. Infectious Diseases Society of America and American Society of Blood and Marrow Transplantation. Summary of the guidelines for prevention of opportunistic infections among hematologic stem cell transplant recipients. Clin Infect Dis 2001 33 : 139 144.
8. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 : 17 : 770 782.
9. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007, Art. No.: CD005590. DOI :.
10. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis Pneumonia in immunocompromised non-HIV-infected patients: Systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007 : 32 : 1052 1059.
11. Vasconcelles MJ, Bernardo MVP, King C, Weller EA, Antin JH. Aerosolized pentamidine as Pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increase risk of other infections. Biol Blood Marrow Transplant 2000 : 6 : 35 43.
12. Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: A 20 year experience. Bone Marrow Transplant 1994 : 13 : 549 557.
13. Souza JP, Boeckh M, Gooley TA, Flowers MED, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999 : 29 : 1467 1471.
14. Maltezou HC, Petropoulos D, Choroszy M, et al. Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant 1997 : 20 : 879 881.
15. Mohle-Boetani J, Akula SK, Holodniy M, Katzenstain D, Garcia G. The suolfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia. West J Med 1992 : 156 : 303 306.
16. Plotkin JS, Buell JF, Njoku MJ, et al. Methemoglobinemia associated with dapsone treatment in solid organ transplant recipients: A two-case report and review. Liver Transplant Surg 1997 : 3 : 149 152.
17. Fishman JA. Prevention of infection due to a Pneumocystis carinii. Antimicrob Agent Chemother 1998 : 42 : 995 1004.
18. Saukkonen K, Garland R, Koziel H. Aerosolized pentamidine as an alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Chest 1996 : 109 : 1250 1255.
19. Kim SY, Dabb AA, Glenn DJ, Snyder KM, Chuk MK, Loeb DM. Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatr Blood Cancer 2008 : 50 : 779 783.
20. Ena J, Amador C, Pasquau F, et al. Once-a month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 1994 : 18 : 901 904.
21. Baggish Al, Hill DR. Antiparasitic agent atovaquone. Antimicrob Agents Chemother 2002 : 46 : 1163 1173.
22. Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999 : 180 : 369 376.
23. Hughes WT, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprime-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993 : 328 : 1521 1527.
24. Fischl MA, Dickinson GM. Fansidar prophylaxis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986 : 105 : 629.
25. Foot AB, Garin YJ, Ribaud P, Devergie A, Derouin F, Gluckman E. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine in bone marrow transplant recipients. Bone Marrow Transplant 1994 : 14 : 241 245.
26. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995 : 122 : 755 761.
27. Schurmann D, Bergmann F, Albrecht H, et al. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection. Eur J Clin Microhbiol Infect Dis 2002 : 21 : 353 361.
28. Teira R, Virosta M, Munoz J, Zubero Z, Santamaria JM. The safety of pyrimethamine and sulfadoxine for the prevention of Pneumocystis carinii pneumonia. Scand J Infect Dis 1997 : 29 : 595 596.
29. Girard PM, Lepetre A, Detruchis P, Matheron S, Coulaud JP. Failure of pyrimethamine-clindamycin combination for prophylaxis of Pneumocystis carinii pneumonia. Lancet 1989 : i : 1459.
30. Lee CH, Crane L, Katz J, Meshnick SR. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000 : 182 : 551 557.
31. Kazanjian P, Locke AB, Hossler PA, et al. Pneumocystis carinii mutations associated with sulfamethoxazole and sulfone prophylaxis failures in AIDS patients. AIDS 1998 : 12 : 873 878.
32. Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet 1998 : 351 : 1631 1632.
33. Navin TR, Beard CB, Huang L, et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of Pneumocystis carinii pneumonia in patients with HIV-1: A prospective study. Lancet 2001 : 358 : 545 549.
34. Visconti E, Ortona E, Margutti P, et al. Successful treatment of PCP episodes caused by Pneumocystis carinii with mutant dihydropteroate (DHPS) gene. J Eukaryot Microbiol 1999 : 46 : 135S.
35. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii cytochrome b mutations are associated with atopovaquone exposure in patients with AIDS. J Infect Dis 2001 : 183 : 819 822.
36. Nahimana A, Rabodonirina M, Zanetti G, et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and negative patients. J Infect Dis 2003 : 188 : 1017 1023.
37. Martino R, Bretagne S, Einsele H, et al. Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood after allogeneic stem cell transplantation. Clin Infect Dis 2005 : 40 : 79 81.
38. Chandrasekar PH. Real-time polymerase chain reaction for early diagnosis of toxoplasmosis in stem cell transplant recipients: Ready for prime time? Clin Infect Dis 2005 : 40 : 67 78.